摘要
目的探讨联合检测糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原153(CA153)、人体绒膜促性腺激素(HCG)四种肿瘤标记物对卵巢癌的诊断价值。方法选取本院收治的35例卵巢癌患者为恶性组,35例良性卵巢肿瘤患者为良性组,35例健康体检者为对照组,观察比较三组血液中CA125、CEA、CA153、HCG的水平差异及其对卵巢肿瘤诊断的价值。结果①与良性组及对照组相比,恶性组 CA125、CEA、CA153、HCG四项指标均明显升高,且差异有显著性(P< 0.05);与对照组比较,良性组CA125与 HCG明显升高(P< 0.05),CEA、CA153两组比较差异无显著性(P >0.05)。②恶性组四项肿瘤标记物阳性检出率明显高于良性组(P< 0.05),对照组检出率为0;③与单项检测相比,联合检测在敏感性(94.3%)、阳性预测值(89.2%)、阴性预测值(94%)以及诊断效率(91.4%)有明显优势,其差异有显著性(P< 0.05)。结论同时检测CA125、CEA、CA153、HCG诊断卵巢癌效率高,其对卵巢癌的防治有重要的临床意义,值得在临床上推广应用。
Objective]To explore the value of combination detection of carbohydrate antigen 125(CA125), carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153)and human chorionic gonadotrophin(HCG)in the diagnosis of ovarian cancer.[Methods]A total of 35 patients with ovarian cancer in our hospital were chosen as malignant group,and 35 patients with benign ovarian tumor were chosen as benign group,and 35 healthy per-sons were chosen as control group.The levels of CA125,CEA,CA153 and HCG in blood among 3 groups were observed and compared,and their value in the diagnosis of ovarian tumors was discussed.[Results]Compared with benign group and control group,the levels of CA125,CEA,CA153 and HCG in malignant group were in-creased obviously,and there was significant difference(P 〈 0.05).Compared with control group,the levels of CA125 and HCG in benign group were increased obviously(P〈 0.05),but there was no significance difference on CEA and CA153 between these two groups(P 〉0.05).The positive rate of four tumor markers in malignant group was obviously higher than that in benign group(P 〈 0.05),and the positive rate in control group was 0. The sensitivity(94.3%),positive predictive value(89.2%),negative predictive value(94%)and diagnosis effi-ciency(9 1 .4%)of the combination detection were higher than those of four single marker detection,and there was significant difference(P〈 0.05).[Conclusion]The combination detection of CA125,CEA,CA153 and HCG for the diagnosis of ovarian cancer has high efficiency and is of great significance in the prevention of ovarian cancer. Therefore,it is worthy of clinical promotion.
出处
《医学临床研究》
CAS
2014年第12期2340-2342,共3页
Journal of Clinical Research